Clinical Trials
Enrolling Trials
81-90 of 168
CIRB, MATCH Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR
Mutations
Adult
MATCH Treatment Subprotocol Z1L
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
CIRB, Molecular Analysis for Therapy Choice (MATCH): EAY131-L: MATCH Treatment Subprotocol L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations
Mutations
Adult
This phase II trial studies how well veliparib, radiation therapy, and temozolomide work in treating participants with newly diagnosed malignant glioma without H3 K27M or BRAFV600E mutations. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving veliparib, radiation therapy, and temozolomide may work better in treating participants with newly diagnosed malignant glioma without H3 K27M or BRAFV600E mutations.
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
CIRB, Molecular Analysis for Therapy Choice (MATCH): EAY131-M: MATCH Treatment Subprotocol M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations
Mutations
Adult
This subprotocol (EAY131-M) should be used in conjunction with the MATCH Master Protocol (EAY131).
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
CIRB, MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutation
Mutations
Adult
The purpose of this study is to test any good and bad effects of the study drug GDC-0449 (vismodegib) in patients whose cancer has genetic changes in the genes Smoothened and Patched 1.
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
CIRB, MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor)
Mutations
Adult
Data Repository - IRB Expedited Approval (SP# WEI30611). For reporting purposes only Prescreen Failure (Disease Team/Site Specific) in VELOS was created. Each disease site is NOT a separate IRB approved study, all data is applicable under SP# WEI30611.
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
CIRB, Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol Z1E: EAY131-Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions
Mutations
Adult
qatest
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
CIRB, MATCH Treatment Subprotocol Z1K: Ipatasertib in Patients with Tumors with AKT Mutations
Mutations
Adult
MATCH Treatment Subprotocol Z1K
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
CIRB, MATCH Treatment Subprotocol Z1L: BVD-523FB (Ulixertinib) in Patients with Tumors with BRAF Fusions, or Non-V600E, Non-V600K BRAF Mutations
Mutations
Adult
MATCH Treatment Subprotocol Z1L
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
Functional Magnetic Resonance Imaging (fMRI) of the Brain in Individuals with Bardet-Biedl Syndrome: focus on receptive and expressive language center
Nephrology
Child
The purpose of this study is to examine possible anatomic differences in brain receptive and expressive language centers in Bardet-Biedl syndrome (BBS) compared to normal age and gender matched monolingual controls using functional magnetic resonance imaging 9fMARI).
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
Development and Implementation of a Pilot Universal Newborn Screening Program for Congenital Cytomegalorvirus Infection (cCMV) across Marshfield Clini
ct.govtest1
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449